Byzova
T.V., Plow E.F. 2000. The PlA2 allele and cardiovascular
disease: the pro33 and con. - The Journal of Clinical
Investigation,
105: 697-698.
Gregg D., Clermont P.J.G. 2003. Platelets
and Cardiovascular Disease. – Circulation, 108: e88-90.
Jackson S.P., Schoenwaelder S.M. 2003. Antiplatelet
therapy: in search of the ‘magic bullet’. - Nature Reviews Drug Discovery, 2: 775-789.
Lefkovits
J., Plow E.F., Topol. E.J. 1995. Platelet glycoprotein IIb/III a
receptors in cardiovscular medicine. – The New England journal of medicine.
332: 1553 - 1557.
Mikkelson
J., Perola M., Karhunen P.J. 2005. Genetics of ptatelet
glycoprotein receptors: risk of trombotic events and pharmacogenetic
implications. - Clinical
and applied thrombosis/hemostasis,
11: 113-125.
Newman
P.J., Derbes R.S., Aster R.H. 1988. The human platelet alloantigens,
PlA1 and PlA2, are associated with a leucine33/proline33
amino acid polymorphism in membrane glycoprotein IIIa, and are
distinguishable
by DNA typing. - The Journal of Clinical Investigation, 83: 1178-1781.
Ruggeri
Z.M. 2002. Platelets in atherothrombosis. - Nature Medicine, 8:
1227-1233.
Zimrin
A.B., Gidwitz S., Lord S., Schwartz E., Bennett J.S. 1990. The
genomic organization of platelet glycoprotein IIIa. – The Journal of
Biological
Chemistry, 265: 8590-8595.